

Multiple Sclerosis: Altered Expression of 70- and 27-kDa Heat Shock Proteins in Lesions and Myelin

DENNIS A. AQUINO, PhD, ELISABETTA CAPELLO, MD, JASON WEISSTEIN, MPH, VIRGINIA SANDERS, PhD, CARMEN LOPEZ, BS, WALLACE W. TOURTELLOTTI, MD, PhD, CELIA F. BROSNAN, PhD, CEDRIC S. RAINE, PhD, DSC, AND WILLIAM T. NORTON, PhD

Abstract. Recent studies have implicated heat shock proteins (HSP) in the pathogenesis of the multiple sclerosis (MS) lesion. Expression of the 73 kDa constitutive HSP (HSC70), the 72 kDa stress-inducible HSP (HSP70), and the 27 kDa small HSP (HSP27) was analyzed in white matter and myelin from central nervous system (CNS) tissue of MS and normal subjects using a combination of immunocytochemistry and quantitative immunoblotting. Plaques of all types were sharply defined by reduced immunostaining for HSC70, and shown by immunoblotting to contain 30 to 50% less HSC70 than surrounding white matter or normal tissue. In contrast, HSP27 was markedly enhanced 2.5- to 4-fold in plaque regions, especially in fibrous astrocytes and in hyperplastic interfacial oligodendrocytes at the lesion edge. HSP70 was less abundant than HSC70, and no significant differences in HSP70 levels were noted between MS and normal white matter. Myelin isolated from active plaques contained 3- to 4-fold more HSC70 than normal myelin. Pronounced expression of HSP70 and HSP27 was also found in MS myelin, although neither protein was detected in normal myelin. Thus, white matter undergoing immune-mediated destruction in MS was associated with altered distribution and expression of HSC70 and HSP27. These changes may initially serve to protect myelin from further destruction and facilitate repair; however, enhanced expression of HSC70, HSP70, and HSP27 in myelin may subsequently present as additional immune targets involved in the progression of disease.

INTRODUCTION

When exposed to elevated temperatures or other adverse conditions, cells from all organisms respond by upregulating the expression of a class of proteins known as heat shock proteins (HSP) that are thought to function in a universal cellular defense mechanism (1). Although first identified as being induced under conditions of stress, most HSP exist constitutively and have been shown to be important to the normal functioning of a cell. The most widely studied HSP are members of the 70 kDa family, which includes the inducible 72 kDa HSP70 and the constitutive 73 kDa HSC70. These 2 proteins are generally localized in the cytosol (however, they can also be found in the nucleus, particularly following stress), exhibit extensive sequence homology (>90%), interact with one another, and perform similar functions (2). It is unclear why both of these proteins are necessary. However, our findings and those of others suggest that different transcriptional and translational control mechanisms regulate HSP70 and HSC70 (3-5).

The role(s) of HSP in multiple sclerosis (MS), an inflammatory demyelinating disease of the human central nervous system (CNS), has recently increased in prominence. Interest in HSP in MS stems mostly from the high immunogenicity and evolutionary conservation of HSP.

These properties have suggested that HSP can act as potential autoantigens and trigger, amplify, and/or modify an autoimmune response. Several lines of evidence support this hypothesis: (a) increased expression of HSP has been noted at the cartilage-pannus junction in rheumatoid joints and in β -cells of the pancreas in autoimmune forms of arthritis and diabetes, respectively; (b) HSP-reactive T cells have been detected in these autoimmune diseases (6-10); (c) in adjuvant arthritis, an animal model, disease can be adoptively-transferred to naive animals by HSP-reactive T cell lines; and (d) both adjuvant arthritis and autoimmune mouse diabetes can be blocked by immunization with HSP antigen using a regimen that results in the induction of tolerance rather than sensitization (6-11). Several laboratories have shown an elevated T cell response to the 60- and 70-kDa HSP families in patients with MS (12-15). In addition, van Noort and colleagues (16) detected α B crystallin (a 23 kDa HSP) in myelin prepared from MS white matter and found that it stimulated a response in peripheral blood monocytes from MS patients that was not found in controls. Their results suggested that α B crystallin may be a prominent target of activated T cells in patients with MS.

The heat shock response is complex, and not necessarily pathogenic. Since HSP play an important role in protecting against environmental stress, their induction may provide a means through which healthy cells are shielded from damage near sites of inflammation or pathology. Also, HSP are important to the normal metabolism of the cell. HSC70 functions as a chaperone, uncoupling ATPase, a microtubule-associated protein, and a molecular chaperone involved in the synthesis of a variety of proteins. We recently presented evidence consistent with a role for HSC70 as a chaperone for myelin

Departments of Neurology (DAA, JW, CL, CSR, WTN), Pathology (EC, CFB, CSR) and Neuroscience (CFB, CSR, WTN), Albert Einstein College of Medicine, Bronx, NY; Brain Research Institute, UCLA, Los Angeles, CA (VS); and Neurology and Research Services, West Los Angeles VA Medical Center, Los Angeles, CA (WWT).

Correspondence to: Dr Dennis A. Aquino, Department of Neurology, F-140, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, New York 10461.

basic protein (MBP) in oligodendrocytes (17). Most work on the small HSP, 27 kDa in humans (HSP27), has been performed in *Xenopus* and *Drosophila*, where it has been shown to play a role in regulating cell division and proliferation and is therefore important in embryogenesis (18, 19). We recently identified HSP27 in human fetal CNS tissue (20), where it may perform similar functions as well as play a role in depolymerizing actin microfilaments (21, 22).

It is unlikely that HSP are the primary or initiating antigens in MS, since in the majority of MS patients, prominent T- and B-cell responses are directed toward myelin antigens (23–25). However, an antibody response to HSP in MS lesions may contribute to the progression of disease. One can speculate that HSP involved in protective and/or regenerative mechanisms in nascent MS lesions may serve as antigens in the chronic plaque and eventually lead to tissue destruction (26). In Alzheimer disease and many other neurodegenerative disorders, elevated expression of HSP (particularly members of the 27-, 60- and 70-kDa families) has been reported; however, evidence of an immune response to HSP is not necessarily present in all cases (16, 27–30). This suggests that the expression and/or distribution of HSP in MS differs from that in other neurological diseases.

To gain additional insight into the role of HSP in MS, we have examined the distribution and level of expression of three HSP—HSC70, HSP70 and HSP27—in white matter and myelin isolated from MS lesions and compared them with normal CNS tissue.

MATERIALS AND METHODS

Tissue Acquisition

For immunocytochemistry, blocks of fresh-frozen CNS tissue obtained between 6 and 8 hours (h) postmortem were available from 4 cases of MS (one with acute/chronic active MS lesions, two with chronic active lesions, and one containing chronic silent lesions) and one normal subject. Tissue was embedded in optimum cooling temperature (OCT) medium, and frozen sections were cut at 8 to 10 μ m. A total of 15 blocks were examined.

For quantitative analysis, blocks of fresh-frozen brain tissue from normal and MS cases were obtained from the National Neurological Research Specimen Bank (West Los Angeles VA Medical Center, Los Angeles, CA) (31). Each block represented a separate brain. Cryosections were prepared from these blocks, and each MS block containing white matter plaque material was classified according to immunological activity and degree of demyelination, as previously described (32). Four blocks of tissue were classified as containing "active" plaques, 4 blocks classified as containing "moderately active" plaques, and 8 blocks classified as containing "least active/inactive" plaques. Also, 4 blocks of tissue were obtained from histologically determined "normal-appearing" white matter that was dissected from MS brains outside of lesion areas. As additional controls, 10 blocks were obtained from white matter regions of

normal, non-MS brains. For comparison, 8 blocks of predominantly gray matter regions of normal, non-MS brains were obtained through the generosity of Dr Peter Davies (Department of Pathology, Albert Einstein College of Medicine). Postmortem times ranged from 6 to 23 h.

Immunocytochemistry

Frozen sections of CNS tissue were air-dried, fixed in acetone for 10 minutes (min), washed, quenched with 0.03% H₂O₂, blocked with normal serum (dependent upon the species in which the secondary antibody was raised), incubated overnight at 4°C with monoclonal antibodies diluted in blocking solution, and stained using the avidin-biotin-peroxidase complex (ABC) technique (Vector Laboratories, Burlingame, CA) with 3,3'-diaminobenzidine (DAB) as chromogen. Two primary antibodies (Affinity BioReagents, Neslake Station, NJ) were used; one reacts with both HSC70 and HSP70 (clone 3a3; 1:25), the other with HSP27 (clone G3.1; 1:100). These monoclonal antibodies worked optimally for immunostaining, and the ones listed below for immunoblotting. All are highly specific and well characterized (2, 3, 33, 34). For negative controls, primary antibodies were substituted by isotype-matched antibodies to irrelevant antigens.

Quantitative Immunoblotting

Portions of frozen tissue from normal and immunocytochemically-classified MS white matter (0.2 to 0.6 g from each block) were homogenized in 8 M urea, and the content of HSC70 and HSP27 determined by quantitative immunoblotting (20, 35/36). Aliquots of each tissue homogenate were boiled in sample buffer containing 1% (wt/vol) SDS, resolved on SDS-PAGE along with HSP27 (clone G3.1; 1:1000), and one with only HSP70 (clone C92F3A-5; 1:1000), and one with HSP27 (clone G3.1, as for immunocytochemistry; 1:1000). Nitrocellulose membranes were washed, incubated with the appropriate peroxidase-conjugated secondary antibody, washed again, and developed using an enhanced chemiluminescence (ECL) system (Amersham, Arlington Heights, IL). Immunoreactive bands were scanned by densitometry and a standard curve of purified HSC70 or HSP27 (StressGen) was constructed for each immunoblot. Sample volumes were adjusted so that the value for each tissue homogenate fell within the linear range of standard curves with correlation coefficients \geq 0.98. The content of HSC70 and HSP27 was expressed as percent of total proteins in each tissue homogenate.

Myelin Isolation, Protein Determination and Statistical Analysis

Myelin was isolated from blocks of white matter by the method of Norton and Podusko (36), dissolved in 1% SDS, briefly sonicated, and analyzed by immunoblotting, as described above. Isolated myelin displayed a typical protein profile by

Commasie blue staining of SDS gels, and its purity was confirmed by the lack (determined by immunoblotting) of several cytoplasmic proteins, including HSP27 and HSP70 in normal myelin, and GRP78 and GRP94 (stress proteins localized within the lumen of the endoplasmic reticulum) in normal and MS myelin. Antibodies to GRP78 (clone 10C3; 1:5,000) and GRP94 (clone 9G10; 1:10,000) were obtained from StressGen. Protein content was determined by Modified Lowry Protein Assay (Pierce, Rockford, IL), using bovine serum albumin as the standard. Statistical significance was assessed by Student's *t* test, and *p* values less than 0.05 were deemed significant.

RESULTS

HSC70/HSP70 Immunoreactivity in MS Lesions

Frozen sections of CNS tissues from early autopsy MS cases were used to assess the expression of HSC70/HSP70 in MS lesions of different stages. In normal-appearing white matter, immunoreactivity for HSC70/HSP70 was prominent on nerve fibers, consistent with the high expression of HSC70/HSP70 detected in CNS tissue by quantitative immunoblotting (see below). In acute MS lesions, the lesion edge was clearly identifiable by a marked shift in the distribution of HSC70/HSP70 immunoreactivity from nerve fibers in the adjacent white matter to lipid-laden macrophages, and scattered nerve fibers in the lesion center.

In chronic-active MS lesions, adjacent white matter showed intense staining of nerve fibers and myelin sheaths, whereas in the lesion center, immunoreactivity for HSC70/HSP70 on nerve fibers was markedly reduced (Fig. 1A). In addition, many axons within the lesion center showed dystrophic changes, characterized by focal dilatations that were strongly reactive for HSC70/HSP70 (Fig. 1B). Immunoreactivity was also noted on endothelial cells, perivascular macrophages, a few astrocytes, and numerous ramified microglial cells (Fig. 1B, C). In normal white matter, HSC70/HSP70 was widespread, with prominent expression on endothelial cells and astrocytes (Fig. 1D). In the center of chronic-silent lesions, immunoreactivity for HSC70/HSP70 was markedly diminished, except for a few scattered astrocytes that showed positive immunoreactivity (not shown).

HSP27 Immunoreactivity in MS Lesions

Within the centers of chronic-active MS lesions, intense reactivity for HSP27 was noted on reactive astrocytes, some endothelial cells and a few round cells with the features of oligodendrocytes (Fig. 2A–E). At the lesion edge, immunoreactive cells of the latter type were detected in greater numbers, and were arranged in an interfacular pattern, many of them displaying fine processes typical of oligodendrocytes (Fig. 2C, D). As seen for HSC70/HSP70, perivascular macrophages stained heavily for HSP27 (Fig. 2E). In white matter adjacent to the lesion, low-level reactivity was found on occasional

endothelial cells and astrocytes (Fig. 2A), as in normal tissue (Fig. 2F). In chronic-silent lesions, the pattern of reactivity for HSP27 was more restricted to reactive fibrous astrocytes within the lesion center (not shown). This reactivity tapered off rapidly in adjacent normal-appearing white matter.

Quantitative Immunoblotting for HSC70 and HSP27

Representative immunoblots of MS and normal white matter probed for HSC70, HSP70, and HSP27 are illustrated in Figure 3, and quantitative analysis of these data for HSC70 and HSP27 in Figure 4. Dramatically lower levels of HSC70 were present in plaque-containing material from MS white matter compared with either normal-appearing white matter or normal tissue (Fig. 3A). HSP70 was generally present in plaque-containing material to HSC70 (Fig. 3A), and no clear pattern of change and no statistically significant differences in HSP70 were detected between MS and normal tissue and among plaque types (Fig. 3B). For quantification, samples were analyzed on separate gels to augment resolution between HSC70 and HSP70. In white matter regions of normal human brain, HSC70 accounted for $1.64 \pm 0.16\%$ (mean \pm SD) of the total protein content (Fig. 4A). In MS tissue, HSC70 represented $1.19 \pm 0.10\%$ of the total protein in active plaques, $1.02 \pm 0.21\%$ in moderately active plaques, and $0.74 \pm 0.13\%$ in least active/inactive plaques (Fig. 4A). As lesions aged, less HSC70 was expressed. For example, the difference in HSC70 content between active and inactive plaques was found to be statistically significant by Student's *t* test, $p < 0.002$. Since HSC70 was present in myelin (see Figs. 1, 5), the loss of myelin probably accounted for the significant decreases in overall HSC70 content in MS white matter and the trend toward lower HSC70 content as lesions aged.

In contrast to HSC70, marked increases were noted in HSP27 expression (Fig. 3C). In the same samples examined for HSC70 content, HSP27 represented $0.024 \pm 0.010\%$ of the total protein content in white matter regions of normal tissue (Fig. 4B). In MS tissue containing active plaques, HSP27 represented $0.10 \pm 0.03\%$ of the total proteins, $0.060 \pm 0.04\%$ in moderately active plaques, and $0.074 \pm 0.04\%$ in least active/inactive plaques (Fig. 4B). Although HSP27 was elevated in all plaque types, no correlation could be made between plaque activity and HSP27 content.

Levels of HSC70, HSP70, and HSP27 in normal-appearing white matter from MS tissue were comparable to normal controls (Figs. 3, 4). However, normal white matter differed significantly from gray matter with respect to HSC70 and HSP27 content (Fig. 4). Predominantly gray matter regions of normal human brain contained more HSC70 ($2.10 \pm 0.54\%$) and less HSP27 ($0.015 \pm 0.007\%$) than normal white matter.




Fig. 1. HSC70 expression in MS and normal CNS tissue. (A) The edge of a chronic active MS lesion (lesion center towards left) shows positive reactivity on axons and blood vessels within the lesion and on myelin sheaths in the adjacent white matter (arrows) $\times 120$. (B) Detail of the lesion area in (A) to show HSC70 immunoreactivity on astrocytes (arrow), endothelial cells of a small blood vessel (*), and a beaded, demyelinated axon (ax). $\times 750$. (C) At the margin of a chronic active MS lesion, the perivascular cuff of HSC70⁺ macrophages is seen. Note also the twig-like background staining of fibrous astroglial cell processes and in the adjacent white matter (upper right), some myelin staining. $\times 480$. (D) HSC70 expression is shown in the white matter from a normal subject. Note the intense staining of the blood vessel (center) and many surrounding astrocytes (arrows). The background matrix shows a higher level of reactivity than in MS lesions (c.f. panel B). $\times 480$.

HSC70, HSP70 and HSP27 in Myelin

Myelin was isolated from 2 representative normal white matter samples (Fig. 5, lanes 1 and 2) and 4 active MS plaques (Fig. 5, lanes 3–6), and immunoblotted for HSC70/HSP70 (Fig. 5A) and HSP27 (Fig. 5B). Both normal myelin samples contained similar amounts of HSC70; however, no HSP70 or HSP27 was detected. HSC70 levels were increased approximately 4-fold in 3 out of 4 cases in myelin isolated from active MS lesions. Moreover, substantial amounts of HSP70 and HSP27

were found in MS myelin. HSC70 was consistently more abundant than HSP70 in MS myelin, and the variability in HSP levels among MS samples was possibly due to regional differences.

DISCUSSION

In this study, we compared the distribution and expression of HSC70, HSP70 and HSP27 between normal and MS white matter by a combination of immunocytochemistry and quantitative immunoblotting. Strikingly




Fig. 2. HSP27 expression in MS and normal CNS tissue. (A) Fibrous astrocytes (arrows) within a chronic active MS lesion (left) display positivity for HSP27, while the adjacent myelinated white matter (right) shows little reactivity. $\times 75$. (B) Within a chronic active MS lesion, numerous fibrous astrocytes display intense reactivity for HSP27. Note also the heavy staining of the background matrix material. $\times 480$. (C) The myelinated edge of another chronic active MS lesion shows intense immunoreactivity for HSP27 on chains of interfascicular oligodendrocytes at numbers suggestive of hyperplasia. The lesion center is to the lower left. $\times 120$. (D) Higher magnification of the same lesion in (C) to show the typical oligodendroglial morphology of the HSP27




Fig. 3. Immunoblotting for HSC70, HSP70 and HSP27 in MS and normal white matter. To illustrate the differences in heat shock protein content in white matter from MS and normal cases, gels were loaded with equal amounts of total protein and immunoblots were probed with antibodies to (A) HSC70 (upper band)/HSP70 (lower band), (B) HSP70, and (C) HSP27. The following amounts of protein were loaded: (A) 5 μ g; (B) 12 μ g; and (C) 20 μ g. Samples were loaded on each gel in the same order. Lanes 1 to 15 represent plaque-containing white matter from MS cases. Active plaques are illustrated in Lanes 3, 6 and 7; moderately active plaques in Lanes 1, 2, 5 and 14; and inactive plaques in Lanes 4, 8 to 13 and 15. Lanes 16 to 19 represent normal-appearing white matter (NAWM) from MS cases, and Lanes 20 to 25 represent white matter from normal subjects.

changes were noted in MS white matter, including: (a) significantly lower levels of HSC70 (30–50%); plaque regions were sharply defined by the loss of HSC70 relative to surrounding white matter; (b) significantly higher levels of HSP27 (2.5- to 4-fold); plaques that stained heavily for HSP27 and contrasted sharply with surrounding white matter; (c) increased expression of myelin-associated HSC70 (3- to 4-fold); and (d) prominent expression of myelin-associated HSP27 and HSP70, which were absent in normal myelin.

Immunocytochemical staining demonstrated that HSC70 was widely distributed in normal-appearing white matter (reflecting its constitutive expression in all cell types) and was present in myelin sheaths. However, HSC70 staining was dramatically reduced within plaques of all types, and decreasing levels of HSC70 as lesions aged were consistent with the loss of myelin. Within the active lesion, demyelinated axons were strongly positive

for HSC70. In correlating the quantitative and immunocytochemical data, it appeared that even though a large proportion of HSC70 content was lost from lesioned white matter, levels of myelin-associated HSC70 were higher in the remaining myelin or in newly-synthesized myelin. Evidence of remyelination was present in the lesions, particularly at the edge of the lesion. Thus, it appeared that in MS white matter, although enhanced expression of HSC70 occurred in specific cellular compartments, overall losses were greater as the disease progressed. In contrast to HSC70, HSP27 content was increased in the same samples of MS white matter. Enhanced immunostaining for HSP27 was evident mostly in reactive astrocytes, myelin and hyperplastic interstitial oligodendrocytes along the lesion edge. These HSP27-oligodendrocytes were arranged in linear arrays and clearly displayed the phenotype, i.e. round cell bodies and short, fine processes, distinctive of this cell type

cells. Note the short, fine processes radiating from some of the cells (arrows). An occasional astrocyte (*) is also shown. Lesion center is to the left. $\times 300$. (E) Perivascular macrophages in an acute MS lesion show heavy staining for HSP27, while the processes of fibrous astrocytes are somewhat less positive. $\times 480$. (F) An area of white matter from a normal subject shows selective immunoreactivity for HSP27 on fibrous astrocytes and a very low background level of reactivity, in contrast to the situation in MS (cf. panel B). $\times 300$.




Fig. 4. Quantification of HSC70 and HSP27 in MS and normal white and gray matter. Levels of HSC70 (A) and HSP27 (B) in brain tissue were quantified by immunoblotting alongside a series of purified protein that was used to generate a standard curve, and expressed as percentage of total protein content in each sample. Data are reported as means \pm SD. Values that were found by Student's *t* test to be statistically different from normal white matter controls are noted: (A) * ($p < 0.05$), ** ($p < 0.005$), *** ($p < 0.002$), **** ($p < 0.0001$); (B) * ($p < 0.05$), ** ($p < 0.01$). NAWM: normal-appearing white matter from MS brains.

It is presently unclear why HSC70, HSP70 and HSP27 would be elevated in myelin isolated from active MS lesions; however, it is possible that these myelin-associated HSP may participate as part of a protective mechanism acting to prevent further destruction of the myelin sheath. In addition, we recently presented evidence consistent with a role of HSC70 as a chaperone for MBP (17). Additional work has shown that (a) MBP-HSC70 complexes exist in oligodendrocytes; and (b) denatured MBP associates into high molecular weight complexes with HSC70 during renaturation (Aquino et al. manuscript in preparation). Thus, increased levels of myelin-associated HSP may be necessary to aid in lesion

repair by ensuring that extrinsic myelin proteins properly associate with the myelin membrane and by preventing proteolysis, aggregation and non-functional interactions during this process. On the other hand, this would suggest that decreased HSC70 content in MS white matter may contribute to demyelination or the lack of efficient and complete remyelination that is evident in MS, since under such circumstances myelin proteins may not be adequately chaperoned.

HSP27 is a chaperone as well (37, 38). It is interesting to note that HSP27 was present only in lesioned myelin and was prominent in oligodendrocytes at the lesion edge, that are actively involved in the remyelination process. Unlike HSC70, which was present in normal myelin, HSP27 is probably not a primary chaperone of myelin proteins and is not likely involved in the maintenance of myelin, but may be recruited to the myelin sheath during times of stress or repair.

In this study, HSC70 and HSP27 levels were determined relative to the total protein content of homogenates prepared from normal and MS white matter containing plaques of different ages. By using purified HSC70 and HSP27 as standards, we were able to compare measurements from a large number of clinical samples since all were normalized against a common standard. Although in most cases statistical variation within each sample classification was minimal, that which was noted may be due to regional differences or varying amounts of normal-appearing tissue surrounding plaque areas that was taken during dissection. In previous studies using this same technique, we found levels of HSC70 and HSP27 in fetal human brain and adult rat spinal cord (3, 6) similar to those reported here for normal adult human brain. In the present study, we found that HSC70 content was greater in normal gray matter than in white matter, while the reverse was true for HSP27. In general, this probably reflected a high expression of HSC70 among neuronal populations and a glial localization for HSP27, as has been reported (3, 20, 39, 40).

It is interesting to note that during the process of remyelination, additional (and possibly novel) immunogenic epitopes may be expressed in myelin. This has been demonstrated in the detection of an elevated T cell response to exon 2 of MBP in patients with MS (41). Exon 2-containing MBP isoforms are relatively minor in the adult, yet their expression is high during developmental myelin formation (42) and during remyelination in MS (43). As in myelogenesis, chaperones should be similarly required for remyelination during the process of lesion repair in MS. However, enhanced membrane expression of these HSP positions them as potential targets of the immune response and consequently may contribute to the progression of chronic MS. Such has been proposed for α B-crystallin, a small HSP, which is not present in normal myelin but is present in myelin isolated from




Fig. 5. HSC70, HSP70 and HSP27 in myelin. Myelin was purified from 2 separate samples of human white matter from normal subjects (Lanes 1 and 2) and 4 separate samples of MS white matter containing active plaques (Lanes 3 to 6). Myelin proteins were resolved by SDS-PAGE and immunoblotted for (A) HSC70 (upper band/HSP70 (lower band) and (B) HSP27. Equal amounts of myelin proteins were loaded per lane in each panel, 40 µg for HSC70/HSP70 and 90 µg for HSP27.

MS tissue (16). Although HSP alone may serve as the immune targets, it is also possible that novel antigens may result from the association of a chaperone and its substrate (e.g. HSC70 and MBP, respectively). Both HSC70 and MBP are highly immunogenic (15).

In conclusion, we found that white matter undergoing immune-mediated destruction was associated with an altered distribution and expression of HSC70 and HSP27. The factors responsible for these changes are unknown. However, cytokines are likely candidates since both IL-1 and TNF α are found at high levels in MS lesions (44, 45) and have been shown to induce synthesis of HSP in cells of the CNS (15, 46). Furthermore, our findings that HSC70, HSP70 and HSP27 were present in myelin isolated from lesioned white matter in MS are novel and contribute to the growing interest in the role of HSP in the pathogenesis of this disease. It is intriguing to speculate that these HSP, which initially may function to protect myelin from damage and aid in its regeneration, eventually may serve as additional targets of the immune response and contribute to the progression of chronic MS.

ACKNOWLEDGMENTS

The authors are grateful to Dr. Damin Peng for her technical expertise in the isolation of myelin. This research was supported by grants RG-1089, RG-2657, and RG-1001 from the National Multiple Sclerosis Society, and by grants NS-23705, NS-08952, NS-30319, NS-02476, and NS-11920 from the National Institutes of Health. The National Neurological Research Specimen Bank is sponsored by NINDS/NIMH, National Multiple Sclerosis Society, Hereditary Disease Foundation, and Veterans Health Services and Research Administration, Department of Veterans Affairs.

REFERENCES

1. Aquino DA, Brosnan CE Heat-shock proteins and immunopathology: An overview. *Chem Immunol* 1992;53:1-16.
2. Brown CR, Martin RL, Hansen WJ, Beckmann RP, Welch WJ. The constitutive and stress inducible forms of hsp 70 exhibit functional similarities and interact with one another in an ATP-dependent fashion. *J Cell Biol* 1993;120:1101-12
3. Aquino DA, Kiplert AA, Brosnan CF, Norton WT. The 70-kDa heat shock cognate protein (HSC70) is a major constituent of the central nervous system and is up-regulated only at the mRNA level in acute experimental autoimmune encephalomyelitis. *J Neurochem* 1993;61:1340-48
4. Kawagoe J, Abe K, Sato S, Nagumo I, Nakamura S, Kogure K-C. Distributions of heat shock protein (HSP) 70 and heat shock cognate protein (HSC) 70 mRNAs after transient focal ischemia in rat brain. *Brain Res* 1992;587:195-202
5. Miller EK, Reese JD, Morrison-Bogorad M. Expression of heat shock protein 70 and heat shock cognate 70 messenger RNAs in rat cortex and cerebellum after heat shock or amphetamine treatment. *J Neurochem* 1991;56:2060-71
6. Cohen IR. Autoimmunity to chaperonins in the pathogenesis of arthritis and diabetes. *Annu Rev Immunol* 1991;9:567-89
7. Yang XD, Feige U. The 65 kD heat shock protein: A key molecule mediating the development of autoimmune arthritis? *Autoimmunity* 1991;9:85-88
8. Anderson SM, van der Zee R, Pralbak B, Noortdij A, van Eden W. Activation of T cells recognizing 60 kD heat shock protein can protect against experimental arthritis. *J Exp Med* 1995;181:943-52
9. Boog CJF, de Greeff-Meeder ER, Lucassen MA, et al. Two monoclonal antibodies generated against human hsp60 show reactivity with synovial membranes of patients with juvenile chronic arthritis. *J Exp Med* 1992;175:1805-10
10. Brodzynski K, Martinez V, Gupta RS. Immunocytochemical localization of heat-shock protein 60-related protein in β -cell secretory granules and its altered distribution in non-obese diabetic mice. *Diabetologia* 1992;35:316-24
11. Elias D, Reshef T, Birk OS, van der Zee R, Walker MD, Cohen IR. Vaccination against autoimmune mouse diabetes with a T-cell

- oniome of the human 65-kDa heat shock protein. *Proc Natl Acad Sci USA* 1991;88:3088-91
12. Battistini L, Salvetti M, Rissoni G, Falcone M, Raine CS, Brosnan CF. γ H T cell receptor analysis supports a role for HSP 70 secretion of lymphocytes in multiple sclerosis lesions. *Mol Med* 1995;1:554-62
 13. Stuessin P, Vandevyver C, Mcदार R, et al. Increased frequency of γ H T cells in cerebrospinal fluid and peripheral blood of patients with multiple sclerosis. Reactivity, cytotoxicity, and T cell receptor V gene rearrangements. *J Immunol* 1995;154:4883-94
 14. Salvetti M, Rissoni G, Buttinielli C, et al. The immune response to mycobacterial 70-kDa heat shock proteins frequently involves autoreactive T cells and is quantitatively dysregulated in multiple sclerosis. *J Neuroimmunol* 1996;65:143-53
 15. Brosnan CF, Battistini L, Gao Y-L, Raine CS, Aquino DA. Heat shock proteins and multiple sclerosis: A review. *J Neuropathol Exp Neurol* 1996;55:389-402
 16. van Noort JM, van Scheel AC, Bajramovic JJ, et al. The small heat-shock protein α B-crystallin as candidate autoantigen in multiple sclerosis. *Nature* 1995;375:998-801
 17. Aquino DA, Lopez C, Farooq M. Antisense oligonucleotide to the 70-kDa heat shock cognate protein inhibits synthesis of myelin basic protein. *Neurochem Res* 1996;21:417-22
 18. Ciocea DR, Oesterreich S, Channames GC, McGuire WL, Fuqua SAW. Biological and clinical implications of heat shock protein 27000 (Hsp27): A review. *J Natl Cancer Inst* 1993;85:1558-70
 19. Arrigo A-P, Mehlben P. Expression, cellular location and function of low molecular weight heat shock proteins (Hsp20s) during development of the nervous system. In: Mayer RJ, Brown IR, eds. *Heat shock proteins in the nervous system*. San Diego: Academic Press Inc., 1994:145-67
 20. Aquino DA, Padin C, Perez JM, Peng D, Lyman WD, Chiu F-C. Analysis of glial fibrillary acidic protein, neurofilament protein, actin and heat shock proteins in human fetal brain during the second trimester. *Develop Brain Res* 1996;91:1-10
 21. Miron T, Wilchek M, Geiger B. Characterization of an inhibitor of actin polymerization in vinculin-rich fraction of turkey gizzard smooth muscle. *Eur J Biochem* 1988;178:543-53
 22. Miron T, Vancompennelle K, Vandekerckhove J, Wilchek M, Geiger B. A 25-kD inhibitor of actin polymerization is a low molecular mass heat shock protein. *J Cell Biol* 1991;114:255-61
 23. Oksenberg JR, Panzara MA, Begovitch AB, et al. Selection for T-cell receptor V β -D β -J β gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis. *Nature* 1993;362:368-70
 24. Warren KG, Cutz J, Johnson E, Mielke B. Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclerosis. *Ann Neurol* 1994;35:280-89
 25. Zhang J, Markovic-Plese S, Lacet B, Raus J, Weiner HL, Hafler DA. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. *J Exp Med* 1994;179:973-84
 26. Raine CS, Wu E, Ivanyi J, Katz D, Brosnan CF. Multiple sclerosis: A protective or a pathogenic role for heat shock protein 60 in the central nervous system? *Lab Invest* 1996;75:109-23
 27. Renkawek K, Bosman GJCGM, de Jong WW. Expression of small heat-shock protein hsp 27 in reactive gliosis in Alzheimer disease and other types of dementia. *Acta Neuropathol* 1994;87:511-19
 28. Gao Y-L, Raine CS, Brosnan CF. Humoral responses to hsp 65 in multiple sclerosis and other neurological conditions. *J Neuroimmunol* 1994;49:91-46
 29. Hamos JE, Oblas B, Pulaski-Salo D, Welch WJ, Bole DG, Drachman DA. Expression of heat shock proteins in Alzheimer's disease. *Neurology* 1991;41:345-50
 30. Harrison PJ, Procter AW, Exworthy T, et al. Heat shock protein 70 (hsp70) mRNA expression in human brain: Effects of neurological degenerative disease and animal state. *Neuropathol Appl Neurobiol* 1993;19:10-21
 31. Tourtellotte WW, Rosario IP, Riehl J, Sanders S, Syndulko K. Morphological neurologic research specimen bank. A model for human frozen neurospecimen banking. In: Aletman G, Smith BH, eds. *Encyclopedia of neuroscience*. Amsterdam: Elsevier, 1997. Forthcoming.
 32. Sanders V, Conrad AJ, Tourtellotte WW. On classification of post-mortem multiple sclerosis plaques for neuroscientists. *J Neuroimmunol* 1993;46:207-16
 33. Adams DJ, Haij H, Edwards DP, Bjereke RJ, McGuire WL, Derez J. Immunoprecipitation of a Mr=24,000 estrogen-regulated protein in human breast cancer by monoclonal antibodies. *Cancer Res* 1983;43:4297-4316
 34. Nadler SG, Tepper MA, Schacter B, Mazzucolo CE. Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp70 family of heat shock proteins. *Science* 1992;258:484-86
 35. Aquino DA, Chiu F-C, Brosnan CF, Norton WT. Glial fibrillary acidic protein increases in the spinal cord of Lewis rats with acute experimental autoimmune encephalomyelitis. *J Neurochem* 1988;51:1085-96
 36. Norton WT, Podulso SE. Myelination in rat brain: Method of myelin isolation. *J Neurochem* 1973;21:749-57
 37. Morimoto RI, Tissieres A, Georgopoulos C. Progress and perspectives on the biology of heat shock proteins and molecular chaperones. In: Morimoto RI, Tissieres A, Georgopoulos C, eds. *The Biology of Heat Shock Proteins and Molecular Chaperones*. Plainfield, NJ: Cold Spring Harbor Laboratory Press, 1994:1-30
 38. Jakob U, Giesel M, Engel K, Buchner J. Small heat shock proteins are molecular chaperones. *J Biol Chem* 1993;268:1517-20
 39. Brown IR. Induction of heat shock genes in the mammalian brain by hyperthermia and tissue injury. In: Mayer RJ, Brown IR, eds. *Heat shock proteins in the nervous system*. San Diego: Academic Press Inc., 1994:31-53
 40. Haass C, Klein U, Kloetzel P-M. Developmental expression of *Drosophila melanogaster* small heat-shock proteins. *J Cell Sci* 1990;96:413-18
 41. Voskuhl RR, Robinson ED, Segal BM, et al. HLA restriction and TCR usage of T lymphocytes specific for a novel candidate autoantigen, X2 MBP, in multiple sclerosis. *J Immunol* 1994;153:4834-44
 42. Voskuhl RR, McFarlin DE, Stone R, McFarland HE. T-lymphocyte recognition of a portion of myelin basic protein encoded by an exon expressed during myelination. *J Neuroimmunol* 1993;42:187-92
 43. Capello E, Voskuhl RR, McFarland HE, Raine CS. Multiple sclerosis rosis: Implications of re-expression of a developmental gene (X2 MBP) for repair of chronic lesions. *Ann Neurol* 1997; Forthcoming
 44. Hofman FM, van Hanwehr RJ, Dinarello CA, Mizel SB, Hinton DT, Merrill JE. Immunoregulatory molecules and IL-2 receptors identified in multiple sclerosis brain. *J Immunol* 1986;136:3239-45
 45. Hofman FM, Hinton DR, Johnson K, Merrill JE. Tumor necrosis factor identified in multiple sclerosis brain. *J Exp Med* 1989;170:607-12
 46. D'Souza SD, Aniel JP, Freedman MS. Cytokine induction of heat shock protein expression in human oligodendrocytes: An interleukin-1 mediated mechanism. *J Neuroimmunol* 1994;58:17-24

Received December 17, 1996
 Revision received February 12, 1997
 Accepted February 17, 1997